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Abbreviations 
1321N1-hP2Y2 cells - 1321N1 cells stably expressing the human P2Y2 receptor 
1321N1-hP2Y11 cells - 1321N1 cells stably expressing the human P2Y11 receptor 
95% cl - 95% confidence limits 
ATP - adenosine 5'-triphosphate 
GPCR - G protein-coupled receptors 
IPs - inositol phosphates 
UTP - uridine 5'-triphosphate 
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Abstract 
Biased agonism describes a multi-state model of G protein-coupled receptor activation in which 
each ligand induces a unique structural conformation of the receptor, such that the receptor couples 
differentially to G proteins and other intracellular proteins. P2Y receptors are G protein-coupled 
receptors that are activated by endogenous nucleotides, such as ATP and UTP. A previous report 
suggested that UTP may be a biased agonist at the human P2Y11 receptor, as it increased cytosolic 
[Ca
2+
], but did not induce accumulation of inositol phosphates, whereas ATP did both. The 
mechanism of action of UTP was unclear, so the aim of this study was to characterise the 
interaction of UTP with the P2Y11 receptor in greater detail. Intracellular Ca
2+
 was monitored in 
1321N1 cells stably expressing human P2Y11 receptors using the Ca
2+
-sensitive fluorescent 
indicator, fluo-4. ATP evoked a rapid, concentration-dependent rise in intracellular Ca
2+
, but 
surprisingly, even high concentrations of UTP were ineffective. In contrast, UTP was slightly, but 
significantly more potent than ATP in evoking a rise in intracellular Ca
2+
 in 1321N1 cells stably 
expressing the human P2Y2 receptor, with no difference in the maximum response. Thus the lack of 
response to UTP at hP2Y11 receptors was not due to a problem with the UTP solution. Furthermore, 
coapplying a high concentration of UTP with ATP did not inhibit the response to ATP. Thus 
contrary to a previous report, we find no evidence for an agonist action of UTP at the human P2Y11 
receptor, nor does UTP act as an antagonist. 
 
Keywords:  Biased agonism, P2Y11 receptor, inositol phosphates, intracellular Ca
2+
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Introduction 
In the classical pharmacological model of drug-receptor interaction, all agonists at a G protein-
coupled receptor (GPCR) activate the same G protein(s) and signalling pathways and agonists differ 
only in their affinity for the receptor and efficacy in stimulating the second messenger(s). It is now 
clear, however, that receptors can in fact couple to different G proteins and signalling pathways in 
an agonist-dependent manner, a process termed biased agonism or functional selectivity [1]. For 
example, coupling of the D2-GRSDPLQHUHFHSWRUWR*Įi1*Įi2, *Įi3 DQG*Įo1 varies with the agonist 
used [2] and the relative efficacy of 5-HT2C agonists depends on whether phospholipase C or A2 
activity is measured [3]. Similar results have been reported for a variety of other GPCR, including 
ȝ-opioid, adrenoceptors and vasopressin receptors.  
 These data suggest a multi-state model of GPCR activation in which each ligand induces a 
unique structural conformation of the receptor that couples differentially to G proteins and other 
proteins, such as arrestins, that interact with GPCR. Direct evidence for this model was obtained 
recently by imaging agonist-induced changes in the conformational structure of the E2-adrenoceptor 
[4] and arginine-vasopressin type 2 receptor [5]. In both studies one group of agonists caused the 
cytoplasmic end of helix VI of the receptor to move, shifting the equilibrium towards G protein 
coupling, whilst another group moved the cytoplasmic end of helix VII, leading to binding of E-
arrestin to the receptor.  
 P2Y receptors are activated by endogenous nucleotides, such as adenosine 5'-triphosphate 
(ATP) and uridine 5'-triphosphate (UTP) [6-8], but there are few reports of biased agonism. ATP 
and UTP induce differential interaction of the human P2Y2 receptor ZLWKȕ-arrestins and the 
downstream increase in phosphorylation of ERK elicited by UTP was transient, whereas the 
response to ATP was prolonged [9]. Intriguingly, it has been reported that whilst ATP stimulation 
of the human P2Y11 receptor caused accumulation of inositol phosphates (IPs) and a rise in 
cytosolic [Ca
2+
], UTP had only the latter effect [10]. Thus ATP and UTP appear to interact with the 
P2Y11 receptor to recruit distinct signalling pathways, but how UTP produced its effects is unclear. 
Biased agonism has important implications for rational drug design as it raises the possibility of 
developing new drugs that only activate a desired, beneficial function of a GPCR, thus optimising 
their therapeutic effect. The aim of this study was, therefore, to investigate the mechanisms by 
which UTP increases cytosolic [Ca
2+
] and so characterise biased agonism at P2Y11 receptors in 
greater detail. 
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Methods and Materials 
Culture of 1321N1 cells 
1321N1 cells, a human astrocytoma cell line, stably expressing the human P2Y11 (1321N1-hP2Y11) 
[11] or P2Y2 (1321N1-hP2Y2 ) [12] receptors were maintained in 5% CO2, 95% O2 in a humidified 
incubator at 37qC, in 'XOEHFFR¶VModified Eagles Media (DMEM) supplemented with 10% foetal 
calf serum, 1% non-essential amino acids, 1% penicillin (10,000 units/ml) and streptomycin (10 
mg/ml). For recording intracellular Ca
2+
, the cells were plated onto 13 mm glass coverslips coated 
with poly-L-lysine (0.1 mg/ml). Experiments were performed once a confluent monolayer of cells 
had developed.  
 
Ca
2+
 imaging 
Intracellular Ca
2+
 was monitored using the Ca
2+
-sensitive fluorescent indicator, fluo-4. Cells on a 
coverslip were incubated with fluo-4 AM HVWHUȝ0at room temperature in the dark for at least 1 
hr. The coverslip was then placed in the recording chamber of a Perkin Elmer LS50B luminescence 
spectrophotometer and the cells superfused continuously at 4ml/min and room temperature with 
buffer composed of (mM): NaCl 122; KCl 5; HEPES 10; KH2PO4 0.5; NaH2PO4 0.5; MgCl2 1; 
glucose 11; CaCl2 1.8, titrated to pH 7.3 with NaOH. Fluo-4 fluorescence, measured as arbitrary 
units (AU), in a population of cells was sampled at 10 Hz following stimulation at 494±10 nm and 
the emission recorded at 516±10 nm using FL Winlab software (V4.00.02). ATP and UTP were 
added in the superfusate for 90-120 sec at 10 min intervals. Preliminary experiments showed that 
reproducible responses were evoked under these conditions. Unless indicated otherwise, data were 
normalised by calculating the response in AU as a percentage of the UHVSRQVHWR$73ȝ0 
(1321N1-hP2Y11 cells) or $73ȝ0(1321N1-hP2Y2 cells).  
 
IP formation 
Generation of inositol phosphates (IPs) was measured as described previously [11]. Briefly, 
1321N1-hP2Y11 cells were seeded in 24-well plates at 10
5
 cells per well and assayed 3 days later 
when confluent. Inositol lipids were radiolabeled by incubation of the cells for 24 h with 200 µl 
inositol-free, serum-free DMEM high glucose and 0.4 µCi myo-[
3
H]inositol. No changes of medium 
were made subsequent to the addition of [
3
H]inositol. Drugs were added in 50 µl of a 5-fold 
concentrated solution in 50 mM LiCl, 250 mM HEPES, pH 7.4. Following a 5 min incubation at 
37qC, the medium was aspirated and the assay terminated by adding 0.75 ml boiling 10 mM EDTA, 
pH 8.0. [
3
H]IPs were then resolved by Dowex AG1-X8 columns [13].  
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Data analysis 
Values in the text and figures refer to mean r S.E.M. or geometric mean with 95% confidence 
limits (95% cl) for EC50 values. Data were compared by paired (Ca
2+
 imaging data) and unpaired 
(IP data) t-tests as appropriate. Differences were considered significant if P<0.05.  
 
Drugs, solutions 
ATP (disodium salt) and UTP (sodium salt) (Sigma/RBI, UK) were dissolved in deionised water as 
10 mM stock solutions and diluted in buffer before use. Fluo-4 AM ester (Invitrogen, UK) was 
dissolved in DMSO as a 1 mM stock solution, frozen immediately and stored at -20°C. On the day 
of use it was diluted in buffer before use. 
 
Results 
A previous study reported that ATP and UTP both increased intracellular Ca
2+
 in 1321N1-hP2Y11 
cells [10], so initial experiments were carried out to confirm these data. Figure 1 shows that ATP 
(0.1 - ȝ0HYRNHGDrapid rise in intracellular Ca2+ that was not maintained in the continued 
presence of ATP. The response amplitude was concentration-dependent, with an EC50  ȝ0
(95% cl. 1.8 - ȝ0Q 6XUSULVLQJO\in the same cells, even high concentrations of UTP (10 
ȝ0Q DQGȝ0Q had no effect on intracellular Ca2+ (Figure 1). 
 To confirm that the UTP solution was active, we repeated these experiments in 1321N1-
hP2Y2 cells. Both nucleotides evoked rapid, transient rises in intracellular Ca
2+
 in a concentration-
dependent manner, with EC50 values of 73 nM for UTP (95% cl. 59 - 90 nM) and 176 nM for ATP 
(95% cl. 156 - 199 nM) (n=4 each) (Figure 2). Indeed, UTP was slightly, but significantly more 
potent than ATP (P<0.01), but there was no difference in the maximum response. The lack of 
response to UTP in 1321N1-hP2Y11 cells was not, therefore, due to a problem with the UTP 
solution. 
 These data show that we could not confirm the previous report [10] that UTP acts at the 
hP2Y11 receptor to raise intracellular Ca
2+
. A possible explanation is that UTP did bind to the 
receptor, but for an unknown reason, did not activate it. To address this possibility we determined if 
coadministration of UTP inhibited the response to ATP. Control responses were obtained to ATP (2 
ȝ0DFRQFHQWUDWLRQFORVHWRits EC50. Superfusing 1321N1-hP2Y11 FHOOVZLWK873ȝ0for 
10 min EHIRUHUHDSSO\LQJ$73ȝ0along with 873ȝ0) had no significant effect on the 
response to ATP (Figure 3a,b). 
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 Previous studies on hP2Y11 receptors reported that ATP, but not UTP, induced accumulation 
of IPs [14,15], so we determined if UTP could inhLELWWKLVDFWLRQRI$73873ȝ0DORQHGLG
not alter basal level of IPs (not shown) nor was WKHULVHLQ,3VHOLFLWHGE\$73ȝ0 significantly 
affected by FRDGPLQLVWUDWLRQRI873ȝ0 (Figure 3c). Thus two bioassays of receptor activity 
show that UTP is also not an antagonist at the human P2Y11 receptor. 
 
Discussion 
Biased agonism, a process in which agonists bind the same receptor subtype, but activate different 
signalling pathways, is an important discovery that has implications for rational drug design, as it 
could lead to the development of new therapeutic agents that selectively stimulate beneficial 
functions of a GPCR. A previous study indicated that UTP is a biased agonist at human P2Y11 
receptors, inducing Ca
2+
 mobilisation, so the aim of this study was characterise this action in detail. 
We were, however, unable to replicate UTP agonism. Nucleotides can also act as P2Y receptor 
antagonists [16], but even high concentrations of UTP did not inhibit ATP in two bioassays of 
P2Y11 receptor activity, Ca
2+
 mobilisation and accumulation of IPs. Thus we conclude that UTP is 
neither an agonist nor an antagonist at the human P2Y11 receptor. 
 In this study, ATP evoked a rapid, concentration-dependent rise in intracellular Ca
2+
 with an 
EC50 of 2.1 µM, which is very close to the value of 2.7 µM seen in the earlier study that suggested 
biased agonism at the P2Y11 receptor [10]. We reported previously an EC50 of 8.1 µM for ATP-
induced accumulation of IPs in the same cells [11], which is similar to the value of 12.6 µM 
reported in the earlier study [10] for that response. Thus the potency of ATP seen in the two 
laboratories was essentially the same, suggesting similar levels of P2Y11 receptor expression. This 
is not surprising, as the 1312N1-hP2Y11 cell line used in both studies was generated by two of the 
present authors (CK, RAN) at the University of North Carolina. Despite this, we did not observe a 
rise in intracellular Ca
2+
 when UTP was applied, even at 100 µM, a concentration that was almost 
maximally effective in the earlier study [10]. 1321N1 cells are often used for expression of 
recombinant P2Y receptors because they not express any endogenous P2Y subtypes [6] and the 
earlier study [10] confirmed the absence of mRNA for the UTP-sensitive P2Y2 and P2Y4 receptors 
in the 1321N1-hP2Y11 cells, eliminating those subtypes as the site of action of UTP. Thus it is 
unlikely that the inactivity of UTP in our study was due to differences in the expression of P2Y 
receptors. 
 Several other possible explanations for the difference in the responsiveness to UTP can be 
considered. Contamination by hydrolysis products of UTP is unlikely to be the cause of the 
discrepancy as the previous study monitored UTP purity by HPLC and eliminated its initial 
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breakdown product, uridine 5'-diphosphate, using a creatine phosphokinase regenerating system. In 
contrast, the UTP solution used in the present study was SXUHZLWK8'3DQG
UMP, so if hydrolysis products of UTP were to induce a Ca
2+
 response, it would most likely have 
been seen in our study. Differences in the composition of the extracellular buffer are also unlikely 
to be an explanation, as in both studies the 1321N1-hP2Y11 cells were superfused with a Krebs-
HEPES buffer containing 10 mM HEPES. Although White et al., (2003) gave no further details of 
the buffer composition, any differences in the ions present would have to substantial in order to 
produce such a large difference in the responsiveness to UTP. Consequently, the most feasible 
explanation in our view is contamination of the UTP solution by a non-nucleotide agent acting at a 
receptor that is not a P2Y receptor. 
 In conclusion, we have demonstrated that ATP acts at the human P2Y11 receptor to initiate a 
rise in cytoplasmic Ca
2+
, but this response is neither mimicked nor inhibited by high concentrations 
of UTP. Thus contrary to a previous report, we have found no evidence that UTP is a biased agonist 
at the human P2Y11 receptor. 
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Fig. 1 ATP, but not UTP increases intracellular Ca
2+
 in 1321N1-hP2Y11 cells. 
a) The superimposed traces show fluo-4 fluorescence during superfusion with $73ȝ0XSSHU
WUDFHDQG873ȝ0ORZHUWUDFHIRU90 sec, as indicated by the horizontal bar. Both records 
are from the same population of cells. b) The mean peak amplitude of responses evoked by ATP 
Q DQG873ȝ0Q DQGȝ0Q are shown. Responses are expressed as % of the 
UHVSRQVHWR$73ȝ0. Vertical lines show S.E.M. 
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Fig. 2 ATP and UTP increase intracellular Ca
2+
 in 1321N1-hP2Y2 cells. 
a) The trace shows fluo-4 fluorescence during superfusion with UTP (1 ȝM) for 90 sec, as indicated 
by the horizontal bar. b) The mean peak amplitude of responses evoked by ATP (n=4) and UTP 
(n=4), expressed as % of the response to ATP (1 ȝ09HUWLFDOOLQHVVKRZ6(0 
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Fig. 3 UTP does not inhibit ATP-evoked responses in 1321N1-hP2Y11 cells. 
a) The traces show the rise in intracellular Ca
2+
 evoked by $73ȝ0in the same population of 
cells before (left-hand side) and after superfusion for 10 min with UTP ȝ0right-hand side), 
as indicated by the horizontal bars. b) The mean peak amplitude of responses evoked by ATP (2 
ȝ0in the absence and presence of UTP (100 ȝ0Q 5) are shown. Responses are expressed as % 
of the control response to ATP (2 ȝ0c) The mean basal level of IPs (left-hand column) and the 
PHDQDPSOLWXGHRIUHVSRQVHVHYRNHGE\$73ȝ0LQWKHDEVHQFHPLGGOHFROXPQDQGSUHVHQFH
RI873ȝ0ULJKW-hand column) are shown. n=3. Vertical lines indicate S.E.M. 
